Does Wegovy Cause Vision Problems?

Step 1: understand which vision risk actually applies to you

Not all vision concerns connected to Wegovy are the same, and conflating them creates unnecessary alarm for most people or, worse, false reassurance for the few who genuinely need to act. There are three distinct situations worth separating.

The first is NAION — non-arteritic anterior ischaemic optic neuropathy — a condition where blood supply to the optic nerve is briefly interrupted, causing sudden painless vision loss, usually in one eye. A research letter published in JAMA Ophthalmology in 2024 described a higher observed rate of NAION among semaglutide users compared with a matched group on other medicines. The absolute numbers were small, the study was observational rather than a controlled trial, and the authors were clear that causation could not be confirmed. Regulatory bodies are monitoring the signal. It has not led to a labelling change in the UK at the time of writing, but it is the reason this question has entered public conversation.

The second situation is diabetic retinopathy. People with long-standing, poorly controlled type 2 diabetes can experience a paradoxical worsening of retinopathy when blood-sugar levels improve quickly. This is a recognised phenomenon with several diabetes treatments, not unique to semaglutide. It is documented in prescribing information and discussed in our overview of semaglutide.

The third situation is the one that applies to most Wegovy users: no specific elevated eye risk beyond background population rates. The common side effects are gastrointestinal, not visual.

Step 2: know which symptoms need same-day attention

Whatever your personal risk profile, certain visual symptoms during any treatment warrant prompt medical review rather than a wait-and-see approach. Sudden loss of vision in one or both eyes, blurred or dimmed central vision that appears without warning, or changes to colour perception that come on quickly should be assessed by a doctor or eye specialist the same day.

Gradual, mild blurring that coincides with hunger, dehydration, or low blood sugar is a different matter, it often resolves once you've eaten or had enough to drink. A useful checking habit: cover each eye in turn for a few seconds and compare. If one eye is noticeably worse than the other, or if both seem suddenly foggier than the day before, that is worth a call to your GP rather than waiting for your next prescription review.

People who were managing diabetic retinopathy before starting Wegovy should ensure their ophthalmologist knows they are beginning semaglutide, so a baseline can be recorded and follow-up planned. This is noted in the NHS guidance on Wegovy and aligns with standard prescribing practice.

You can report any suspected side effect, including eye symptoms, through the MHRA Yellow Card scheme. Doing so helps regulators build a clearer picture over time.

Step 3: put the risk in proportion and know what to ask next

Context matters here. Obesity itself is associated with a range of conditions that affect vision, including raised intracranial pressure (idiopathic intracranial hypertension) and worsening diabetic eye disease. The population most likely to use Wegovy is also the population with elevated baseline risk for several of those conditions. That does not mean Wegovy causes eye problems across the board; it means the question of risk requires careful, individual clinical assessment rather than a blanket answer.

If you are considering starting Wegovy and you have a history of eye disease, recent optic nerve problems, or long-standing diabetes with retinopathy, raise it at the consultation stage. A prescriber can weigh it properly. Equally, if you are already on treatment and have noticed visual changes you haven't mentioned yet, our contact page connects you to aftercare support seven days a week.

It is also worth knowing that similar questions arise with other medicines in this class. The wider semaglutide side-effect picture covers everything from gastrointestinal symptoms to less common concerns, and our page on semaglutide and vision goes deeper on the ophthalmological research for anyone who wants the primary evidence. Sleep disruption is another symptom patients sometimes notice; whether Wegovy affects sleep is addressed separately. For stomach-related concerns, this page on gastrointestinal effects is the right starting point.

Wegovy remains a licensed, evidence-backed treatment for weight management. The vision question deserves a straight answer rather than dismissal or alarm, and the straight answer is: most users will not develop eye problems, a small number of people with specific risk factors need closer monitoring, and any sudden visual change during treatment should be checked promptly. If you would like to discuss your personal history before or during treatment, speak to our prescribers through a free consultation.